CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. The company is headquartered in Bethesda, Maryland and currently employs 2 full-time employees. The company went IPO on 2007-07-02. The firm's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The firm indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
Follow-Up Questions
CNBX Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. Eyal Barad은 2017부터 회사에 합류한 CNBX Pharmaceuticals Inc의 Chief Executive Officer입니다.
CNBX 주식의 가격 성능은 어떻습니까?
CNBX의 현재 가격은 $0.0003이며, 전 거래일에 decreased 0% 하였습니다.
CNBX Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
CNBX Pharmaceuticals Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
CNBX Pharmaceuticals Inc의 시가총액은 얼마입니까?
CNBX Pharmaceuticals Inc의 현재 시가총액은 $27752.999999999996입니다
